A Phase 3, randomized, double-blind, placebo-controlled,parallel-group study to investigate the efficacy and safety ofdupilumab for the treatment of pruritus of Lichen SimplexChronicus (LSC) in adults

A new clinical trial will test whether the drug dupilumab can relieve the severe itching of Lichen Simplex Chronicus (LSC), a skin condition that drives people to scratch until their skin thickens into dark, leathery patches. LSC is notoriously difficult to treat. Existing creams and medications often fail or cause unpleasant side effects, leaving many patients with relentless itching that disrupts sleep, work, and daily life. The condition commonly affects the neck, ankles, scalp, and genitals, and the scratching itself worsens the skin damage. Dupilumab already reduces itching in other skin diseases like eczema, so researchers want to see if it works for LSC as well. This phase 3 trial is double-blind and placebo-controlled, meaning neither patients nor doctors will know who receives the real drug. Running across 17 countries and starting in November 2024, each participant will be followed for up to 10 months. If dupilumab proves effective, it could become the first targeted treatment for LSC—offering a safe, reliable option for a condition that currently has none. That would directly improve quality of life for thousands of adults who currently cycle through ineffective therapies.